Literature DB >> 17593502

The risk factors for mortality of community-acquired pneumonia in Japan.

Rei Fujiki1, Tomotaka Kawayama, Toshihiko Ueyama, Masao Ichiki, Hisamichi Aizawa.   

Abstract

Community-acquired pneumonia remains one of the most important diseases associated with mortality. The aim of this study was to identify the risk factors for mortality in patients with community-acquired pneumonia in Japan. This prospective study was carried out at the Social Insurance Tagawa Hospital, Fukuoka, Japan. All patients were managed according to the 1993 American Thoracic Society guidelines for community-acquired pneumonia, after an evaluation of the risk class by the pneumonia Patient Outcome Research Team (PORT) study. A comparison of several factors, including demographic findings, clinical signs, underlying diseases, results of medical examinations, severity of diseases, and causative pathogens in both survival and fatal groups, was carried out from 227 episodes of community-acquired pneumonia in 208 hospitalized patients (128 men, mean age 67.7 years). The presence of a risk of aspiration, low systolic blood pressure, low PaO(2)/FIO(2) ratio, a high pneumonia score, and the presence of severe congestive heart failure were found to be independent risk factors for mortality from community-acquired pneumonia. The mortality in risk classes IV and V was 17.5% and 54.2%, respectively, and there was a significant correlation between risk classes. The risk factors we identify here are generally similar to those given in previous reports in Western countries. According to the prediction rule of the pneumonia PORT study, the risk classes were strongly associated with the mortality, and would be suitable and helpful for the management of patients with community-acquired pneumonia in Japan.

Entities:  

Mesh:

Year:  2007        PMID: 17593502     DOI: 10.1007/s10156-007-0512-0

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

Review 1.  Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.

Authors:  T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

2.  Influence of socioeconomic status on community-acquired pneumonia outcomes in elderly patients requiring hospitalization: a multicenter observational study.

Authors:  Conchita Izquierdo; Manuel Oviedo; Laura Ruiz; Xavier Sintes; Isabel Vera; Manel Nebot; Jose-María Bayas; Jordi Carratalà; Wenceslao Varona; Dolores Sousa; Jose-Miguel Celorrio; Luis Salleras; Angela Domínguez
Journal:  BMC Public Health       Date:  2010-07-15       Impact factor: 3.295

Review 3.  The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review.

Authors:  Leon Peto; Behzad Nadjm; Peter Horby; Ta Thi Dieu Ngan; Rogier van Doorn; Nguyen Van Kinh; Heiman F L Wertheim
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-04-29       Impact factor: 2.184

Review 4.  Prognostic implications of aspiration pneumonia in patients with community acquired pneumonia: A systematic review with meta-analysis.

Authors:  Kosaku Komiya; Bruce K Rubin; Jun-Ichi Kadota; Hiroshi Mukae; Tomohiro Akaba; Hiroshi Moro; Nobumasa Aoki; Hiroki Tsukada; Shingo Noguchi; Nobuaki Shime; Osamu Takahashi; Shigeru Kohno
Journal:  Sci Rep       Date:  2016-12-07       Impact factor: 4.379

5.  N-terminal-pro-B-type-natriuretic peptide associated with 2-year mortality from both cardiovascular and non-cardiovascular origins in prevalent chronic hemodialysis patients.

Authors:  Chihiro Kawagoe; Yuji Sato; Tatsunori Toida; Hideto Nakagawa; Yasuhiro Yamashita; Akihiro Fukuda; Shuji Iwatsubo; Shouichi Fujimoto
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

Review 6.  Community-Acquired Pneumonia in the Asia-Pacific Region.

Authors:  Jae-Hoon Song; Kyungmin Huh; Doo Ryeon Chung
Journal:  Semin Respir Crit Care Med       Date:  2016-12-13       Impact factor: 3.119

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.